PMH15 Development of A Self-Administered Outcome Measure for Use in An Outpatient Population of Individuals with Schizophrenia  by Barr, JT et al.
Abstracts
based on criteria from the Headache Classification Com-
mittee of the International Headache Society. The focus
group meetings consisted of scripted questions that were
both directed and open-ended. The questions addressed
issues relevant to the domains of interest and how they
are impacted by migraines.
RESULTS: The information acquired in the focus groups
was used to develop an 81-item questionnaire with four
open-ended questions and 77 directed questions. The di-
rected questions are scored on a Likert-type scale ranging
from "never when I have a migraine" to "every time I
have a migraine." The content of the instrument ranges
from missing work to taking longer breaks or missing
deadlines.
CONCLUSION: A first-line instrument was developed to
assess migraine-related productivity. The instrument will
next be tested for validity and analyzed for item reduction.
SCHIZOPHRENIA MANAGEMENT: DOES
MANAGED CARE INFLUENCE LENGTH
OF STAY IN U.S. HOSPITALS?
O'Brien JA, Pietrusewicz MJ, Pierce D, Caro JJ
Caro Research, Boston, MA, USA
Insurers' influence on patterns of care and disease man-
agement continues to be questioned in the u.s.
OBJECTIVE: To determine the effect managed care has
on length of stay (LOS) and costs of inpatient manage-
ment of schizophrenia in acute general hospitals.
METHODS: LOS and cost estimates were developed
based on patient-level data from the 1996 Massachusetts
discharge database. Analyses were limited to patients with
a principal diagnosis of schizophrenia (based on ICD9
codes). Three populations were examined: an all payer
group, a standard Medicaid coverage group, and those
with a Medicaid-funded managed care plan (MMC).
Unique patient identifiers enabled examination of annual
admission frequency. All costs are reported in 1996 US$,
adjusted appropriately for cost-to-charge ratios.
RESULTS: Of the 3,500 patients admitted for schizo-
phrenia, 582 (17%) were covered by Medicaid and 419
(12%) by MMC. Overall, patients were admitted an av-
erage of 1.7 times in the year, with 67% having only one
admission. The mean admission rate was 1.8 among
Medicaid patients and 1.6 with MMC; a single admission
occurred in 73% of the Medicaid group and 67% for
MMC. The mean LOS was 14 days for the Medicaid
group compared to 13.5 days for the all payer group and
12.3 days for those with MMC. Among those with only
one admission, the difference increases: 16.4 days for the
Medicaid group, 14.7 days for the all payer group, and
12.9 for the MMC group. Costs for this admission were
correspondingly highest for standard Medicaid ($10,864)
and lowest for MMC ($7,911).
CONCLUSION: The managed care approach decreases
the length of stay and cost of inpatient management of
83
schizophrenia. The appropriateness of these reductions
remains unclear.
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OBJECTIVE: We developed a self-administered, health
status measure to monitor and assess the functional sta-
tus and response to treatment in an outpatient population
of individuals with schizophrenia.
METHODS: 442 adult consumers with schizophrenia
(61% male, 39% female) were recruited from >50 sites
in the Massachusetts mental health system. Consumers
completed 7 administrations of a set of 2 assessment mea-
sures over a 9-month period: a 75-item prototype ques-
tionnaire used to sample subjective and objective con-
sumer and the BASIS-32, a 32-item mental health status
measure. Several staff assessments of consumer status
were also completed at each administration.
RESULTS: The original consumer battery of 107 items
was reduced and modified to 46 using correlation, vari-
ance, item, and factor analyses. The 7 constructs com-
prising the 46 items included-in decreasing order of
contribution to the total variance of the factor analysis-
mental health, work and leisure, self-concept, activities of
daily living, physical function, interpersonal satisfaction,
and medication effects. These 7 constructs explained
63% of the variance, with Cronbach's alpha of 0.94.
Test-retest reliability was approximately 0.8. Item to to-
tal score correlations were all significant and ranged from
0.24 to 0.68. The above set of 46 items was then aug-
mented by 5 additional items gleaned from consumer and
expert panel assessments of item importance to yield a
51-item instrument called the Health Status-S Survey.
CONCLUSION: The Health Status-S Survey appears
practical in a community-based population of individuals
with schizophrenia. The survey is now being validated in
5 states-Arizona, Massachusetts, South Carolina, Wash-
ington, and Wisconsin-using 4 administrations over 3
months for 300 consumers per state.
